Jaz­z's KRAS deal with Redx; Al­to Neu­ro­science up­sizes IPO

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics:

Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion up­front, with mile­stones up to $870 mil­lion. The deal will ex­tend Redx’s run­way in­to 2025.

Al­to Neu­ro­science’s up­sized IPO: The Los Al­tos-based CNS biotech raised $147.9 mil­lion in its ini­tial pub­lic of­fer­ing, sell­ing 9.2 mil­lion shares at $16.00 each.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER